Showing results (21-30 of 470) with videos related to

Sort By:
Pageof 47
The Lancet. Rheumatology|April 3, 2025
Serum type I interferon score as a disease activity biomarker in patients with diffuse cutaneous systemic sclerosis: a retrospective cohort studyMonique Hinchcliff, Dinesh Khanna, Enrico De Lorenzis, et al.
The Lancet. Rheumatology|May 24, 2025
Treatment outcomes in patients with VEXAS syndrome: a retrospective cohort studyAdam Al-Hakim, Roochi Trikha, Ei Ei Phyu Htut, et al.
The Lancet. Rheumatology|May 5, 2025
Long-term effect of anifrolumab on patient-reported outcomes in systemic lupus erythematosus (TULIP-LTE): a randomised, placebo-controlled, phase 3 long-term extension trialVibeke Strand, Kenneth C Kalunian, Kai Wai Lee, et al.
The Lancet. Rheumatology|March 31, 2025
First-line biological versus conventional synthetic disease-modifying antirheumatic drug therapy in adult-onset Still's disease: a multicentre, retrospective, propensity weighted cohort studyAnna Kernder, Tim Filla, Rhea Friedrich, et al.
The Lancet. Rheumatology|September 20, 2025
Patient outcomes from implementing a shared decision-making aid for systemic lupus erythematosus: a prospective implementation studyJasvinder A Singh, Larry R Hearld, Seth Eisen, et al.
The Lancet. Rheumatology|September 1, 2020
Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective studyJennifer C E Lane, James Weaver, Kristin Kostka, et al.
The Lancet. Rheumatology|September 28, 2020
Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort studyChris A Gentry, Mary Beth Humphrey, Sharanjeet K Thind, et al.
The Lancet. Rheumatology|December 21, 2020
Associations between gut microbiota and genetic risk for rheumatoid arthritis in the absence of disease: a cross-sectional studyPhilippa M Wells, Adewale S Adebayo, Ruth C E Bowyer, et al.
The Lancet. Rheumatology|October 5, 2020
Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trialAlexander P J Vlaar, Sanne de Bruin, Matthias Busch, et al.
The Lancet. Rheumatology|October 2, 2020
Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trialViola Klück, Tim L Th A Jansen, Matthijs Janssen, et al.
Pageof 47